<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00887484</url>
  </required_header>
  <id_info>
    <org_study_id>114544</org_study_id>
    <nct_id>NCT00887484</nct_id>
  </id_info>
  <brief_title>A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne</brief_title>
  <official_title>A Single-blind, Randomized, Comparative Pilot Study Evaluating the Tolerability of Two Topical Combination Therapies in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the tolerability of topical combination therapies in
      the treatment of facial acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the tolerability of topical combination therapies in
      the treatment of facial acne.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erythema (Redness)</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Dryness</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Skin Peeling</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irritant/Allergic Contact Dermatitis</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Erythema (Redness)</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Dryness</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Peeling</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritant/Allergic Contact Dermatitis</measure>
    <time_frame>Weeks 5 and 8</time_frame>
    <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigators Static Global Assessment</measure>
    <time_frame>Baseline, Weeks 5, 8</time_frame>
    <description>ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <description>Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <description>Total number of inflammatory acne lesions (pustules, papules) at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-inflammatory Acne Lesion Counts</measure>
    <time_frame>Baseline, Weeks 5 and 8</time_frame>
    <description>Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Emotional Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Functional Domain</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Global Score</measure>
    <time_frame>Baseline, Weeks 2 and 8</time_frame>
    <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Compliance at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2</measure>
    <time_frame>Weeks 1 and 2</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clindoxyl Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epiduo gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will apply both study products in a split-face fashion. Study products will be applied once-daily in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BENZOYL PEROXIDE/ CLINDAMYCIN</intervention_name>
    <description>Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.</description>
    <arm_group_label>Clindoxyl Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BENZOYL PEROXIDE/ ADAPALENE</intervention_name>
    <description>Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.</description>
    <arm_group_label>Epiduo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects at least 21 years of age, in good general health with
             documented diagnosis of acne vulgaris.

          -  Female subjects of childbearing potential must have a negative pregnancy test.
             Sexually active women of childbearing potential participating in the study must use a
             medically acceptable form of contraception Abstinence is considered an acceptable
             method of contraception.

          -  Inflammatory (papules and pustules) and non-inflammatory (open and closed comedones)
             facial lesions.

          -  The ability and willingness to follow all study procedures, attend all scheduled
             visits, and successfully complete the study

          -  Capable of understanding and willing to provide signed and dated written voluntary
             informed consent (and any local or national authorization requirements) before any
             protocol specific procedures are performed

        Exclusion Criteria:

          -  Female subjects who are pregnant, trying to become pregnant or breastfeeding.

          -  Subjects who have any clinically relevant finding at their baseline physical other
             than acne vulgaris.

          -  History or presence of regional enteritis or inflammatory bowel disease (eg,
             ulcerative colitis, pseudomembranous colitis, chronic diarrhea, or a history of
             antibiotic-associated colitis) or similar symptoms.

          -  Use of topical antibiotics or anti-acne medications on the face and systemic
             antibiotics within the past 2 and 4 weeks, respectively.

          -  Use of topical corticosteroids on the face or systemic corticosteroids within the past
             4 weeks. Use of inhaled, intra-articular or intra-lesional (other than for facial acne
             lesions) steroids is acceptable.

          -  Use of systemic retinoids within the past 6 months.

          -  Facial procedures performed by an esthetician, beautician, physician, nurse, or other
             practitioner, within the past 4 weeks or during the conduct of the study.

          -  Known hypersensitivity or previous allergic reaction to any of the active components,
             lincomycin, adapalene, clindamycin, benzoyl peroxide or excipients of the study
             product.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro de Investigación y Prevencion de Enfermidades Cardiovasculares</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1119</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Buenos Aires</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1181 ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LUMIPIEL - Centro Dermatológico</name>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>1181 ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Buenos Aires Skin</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <zip>C1055AAO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2009</study_first_submitted>
  <study_first_submitted_qc>April 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2009</study_first_posted>
  <results_first_submitted>September 22, 2010</results_first_submitted>
  <results_first_submitted_qc>September 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2012</results_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Acne Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>114544</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114544</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114544</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114544</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>114544</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Clinical research center</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Clindoxyl and Epiduo Gels</title>
          <description>Commencing at baseline, participants will apply clindoxyl and epiduo gels once daily in a bilateral split-face fashion (Split Face Treatment Period; allocation to left and right side randomly assigned) for an initial 2 weeks. At Week 5, during the Full Face Treatment Period, participants will apply clindoxyl gel to the entire face for an additional 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Split Face Treatment (Weeks 1 and 2)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Full Face Treatment (Weeks 5 and 8)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Clindoxyl and Epiduo Gels</title>
          <description>Commencing at baseline, participants will apply clindoxyl and epiduo gels once daily in a bilateral split-face fashion (Split Face Treatment Period; allocation to left and right side randomly assigned) for an initial 2 weeks. At Week 5, during the Full Face Treatment Period, participants will apply clindoxyl gel to the entire face for an additional 4 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigators Static Global Assessment (ISGA)</title>
          <description>The investigator rated the participants’ skin using the 6-point ISGA: 0=clear, clear skin with no inflammatory lesions (ILs) or non-ILs; 1=almost clear, rare non-ILs with no more than one small IL; 2=mild, some non-ILs with no more than a few ILs (papules/pustules only, no nodular lesions [NLs]); 3=moderate, up to many non-ILs and may have some ILs, but no more than one small NL; 4=severe, up to many non-IL and ILs, but no more than a few NLs; 5=many non-IL and ILs and more than a few NLs. May have cystic lesions. Participants with grades of 2-4 were eligible for enrollment in this study.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory Acne Lesion Count</title>
          <description>Inflammatory acne lesion count at baseline (number of pustules and papules).</description>
          <units>Inflammatory lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-Inflammatory Acne Lesion Count</title>
          <description>Non-Inflammatory acne lesion count at baseline (number of whiteheads and blackheads)</description>
          <units>Non-Infammatory acne lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Acne Lesion Count</title>
          <description>Total acne lesion count (includes inflammatory and non-inflammatory lesions)</description>
          <units>Acne lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Erythema (Redness)</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>Intent-to-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema (Redness)</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>Intent-to-Treat (ITT)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.70"/>
                    <measurement group_id="O2" value="0.91" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.62"/>
                    <measurement group_id="O2" value="0.74" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythema (Redness)</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythema (Redness)</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Dryness</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Dryness</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Dryness</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Dryness</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.55"/>
                    <measurement group_id="O2" value="0.96" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.58"/>
                    <measurement group_id="O2" value="0.64" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Skin Peeling</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Peeling</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3,Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.52"/>
                    <measurement group_id="O2" value="0.68" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.61"/>
                    <measurement group_id="O2" value="0.60" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Irritant/Allergic Contact Dermatitis</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Irritant/Allergic Contact Dermatitis</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.20"/>
                    <measurement group_id="O2" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.20"/>
                    <measurement group_id="O2" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skin Peeling</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Skin Peeling</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Irritant/Allergic Contact Dermatitis</title>
        <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
        <time_frame>Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Irritant/Allergic Contact Dermatitis</title>
          <description>Signs and symptoms of tolerability (erythema, peeling, dryness, and irritant/allergic contact dermatitis)on the face.
Erythema, peeling, dryness, and irritant/allergic contact dermatitis were graded using the following scale: 0, None; 1, Slight; 2, Moderate; 3, Intense.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigators Static Global Assessment</title>
        <description>ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.</description>
        <time_frame>Baseline, Weeks 5, 8</time_frame>
        <population>For the first 2 weeks, participants apply one of the drugs (Clindoxyl or Epiduo) to one side of the face and the other drug to the other side of their face. After week 2, participants apply Clindoxyl to their entire face and do not use Epiduo.</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigators Static Global Assessment</title>
          <description>ISGA is evaluated using the following scale: 0, Clear: Clear skin with no lesions; 1, Almost Clear: Rare non-inflammatory lesions; 2, Mild: Some non-inflammatory lesions with no more than a few inflammatory lesions but no nodular lesions); 3, Moderate: Up to many non-inflammatory lesions and may have some inflammatory lesions, but no more than 1 small nodular lesion; 4, Severe: Up to many non-inflammatory and inflammatory lesions, but no more than a few nodular lesions; 5, Very Severe: Many non-inflammatory and inflammatory lesions and more than a few nodular lesions. May have cystic lesions.</description>
          <population>For the first 2 weeks, participants apply one of the drugs (Clindoxyl or Epiduo) to one side of the face and the other drug to the other side of their face. After week 2, participants apply Clindoxyl to their entire face and do not use Epiduo.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.77" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.89" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.62" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Acne Lesion Counts</title>
        <description>Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),</description>
        <time_frame>Baseline, Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Acne Lesion Counts</title>
          <description>Total acne lesion counts - includes both inflammatory acne lesions (pustules, papules), noninflammatory lesions (whiteheads and blackheads),</description>
          <population>ITT</population>
          <units>Acne Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.06" spread="12.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.96" spread="10.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.77" spread="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory Acne Lesion Counts</title>
        <description>Total number of inflammatory acne lesions (pustules, papules) at each timepoint.</description>
        <time_frame>Baseline, Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory Acne Lesion Counts</title>
          <description>Total number of inflammatory acne lesions (pustules, papules) at each timepoint.</description>
          <population>ITT</population>
          <units>Acne Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23" spread="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" spread="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-inflammatory Acne Lesion Counts</title>
        <description>Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.</description>
        <time_frame>Baseline, Weeks 5 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-inflammatory Acne Lesion Counts</title>
          <description>Total number of non-inflammatory acne lesions (whiteheads and blackheads) at each timepoint.</description>
          <population>ITT</population>
          <units>Acne Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.83" spread="12.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.36" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.51" spread="8.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain</title>
        <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28.</description>
        <time_frame>Baseline, Weeks 2 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Skindex-29 Quality of Life Questionnaire (QoL) - Symptomatic Domain</title>
          <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The symptomatic score (score=0 to 28)=(sum of the 7 individual item scores) * 100/28.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.91" spread="15.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.58" spread="14.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" spread="14.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire - Emotional Domain</title>
        <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40.</description>
        <time_frame>Baseline, Weeks 2 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire - Emotional Domain</title>
          <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The emotional score (score=0 to 40)=(sum of the 10 individual item scores) * 100/40.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.32" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.38" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.42" spread="19.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire - Functional Domain</title>
        <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48.</description>
        <time_frame>Baseline, Weeks 2 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire - Functional Domain</title>
          <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. The functional score (score=0 to 48)=(sum of the 12 individual item scores) * 100/48.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.30" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaire - Global Score</title>
        <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116.</description>
        <time_frame>Baseline, Weeks 2 and 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaire - Global Score</title>
          <description>Skindex-29 is a self-administered (by participants at each time point) QoL questionnaire comprised of 29 items (it.) scored on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=often, 4=all the time) covering 3 domains: emotional (10 it.); symptomatic (7 it.); functional (12 it.). Domain scores range from 0 to 40, 0 to 28, and 0 to 48, respectively. Lower scores=better QoL. A Global Score (range 0-100)=(sum of all 29 individual item scores) * 100/116.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.59" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.30" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.19" spread="11.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Redness at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="1.18"/>
                    <measurement group_id="O2" value="1.72" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.86"/>
                    <measurement group_id="O2" value="1.15" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Redness at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Dryness at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="1.14"/>
                    <measurement group_id="O2" value="1.81" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" spread="0.87"/>
                    <measurement group_id="O2" value="1.41" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Dryness at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Burning at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="1.23"/>
                    <measurement group_id="O2" value="1.68" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.89"/>
                    <measurement group_id="O2" value="1.30" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Burning at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Itching at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="1.11"/>
                    <measurement group_id="O2" value="1.02" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="0.96"/>
                    <measurement group_id="O2" value="0.93" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Itching at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Scaling at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="1.18"/>
                    <measurement group_id="O2" value="1.43" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.69"/>
                    <measurement group_id="O2" value="1.04" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Severity of Scaling at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 0, None; 1, Very minimal; 2, Mild; 3, Moderate; 4, Severe; 5, Very Severe.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.51"/>
                    <measurement group_id="O2" value="1.32" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.53"/>
                    <measurement group_id="O2" value="1.39" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Ease of Application of Product at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Very easy; 2, Easy; 3, Neutral; 4, Difficult.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Comfort of Skin at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.81" spread="0.88"/>
                    <measurement group_id="O2" value="3.15" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.93"/>
                    <measurement group_id="O2" value="2.67" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Comfort of Skin at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Comfortable; 2, Comfortable; 3, Somewhat Comfortable; 4, Somewhat Uncomfortable; 5, Uncomfortable.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT. Data are presented for only those participants completing the questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>Subjects applied both study products in a split-face fashion through week 2. Study products were applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Which Study Product is Subject More Satisfied With? at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following choices: Epiduo, Clindoxyl Gel, Both Treatments Equally.</description>
          <population>ITT. Data are presented for only those participants completing the questionnaire.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, Epiduo Gel, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Clindoxyl Gel, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Both Treatments Equally, n=47</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Epiduo Gel, n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Clindoxyl Gel, n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Both Treatments Equally, n=46</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to their entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Comparison of Study Products Used in the Past at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, More Satisfied; 2, Somewhat More Satisfied; 3, Neither Satisfied or Dissatisfied; 4, Somewhat More Dissatisfied; 5, More Dissatisfied.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, Uncomfortable.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" spread="0.68"/>
                    <measurement group_id="O2" value="2.04" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.84"/>
                    <measurement group_id="O2" value="2.00" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Decrease of Acne Breakouts by Study Products at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire was completed by the subject at week 8 using the following scale: 1, Highly Favorable; 2, Favorable; 3, Neutral; 4, Unfavorable; 5, More Dissatisfied.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Compliance at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Compliant at all; 1, Mostly Compliant; 2, Very Compliant.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.91" spread="0.28"/>
                    <measurement group_id="O2" value="1.91" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="0.42"/>
                    <measurement group_id="O2" value="1.85" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Compliance at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Compliance at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at week 8 by answering Yes or No to the following question: Did you use the product every day?. When only one product was applied to the face, subjects were asked to rate their compliance by answering the aforementioned question, rather than rating compliance on a 0-2 scale.</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Feeling of Hydrated and Moisturized Skin at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product?</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 - No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Use of Study Product if Choice to Continue Acne Treatment at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at 8 week timepoint by answering Yes or No to the following question: If you were to choose to continue treatment for your acne, would you use the study product?</description>
          <population>ITT</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Ease of Use Wtih Make-Up at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="1.24"/>
                    <measurement group_id="O2" value="2.31" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.93"/>
                    <measurement group_id="O2" value="1.75" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Ease of Use With Make-Up at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 0, Not Applicable; 1, Very Easy; 2, Easy; 3, Neutral; 4, Difficult; 5, Very Difficult.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.69" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
        <time_frame>Weeks 1 and 2</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Clindoxyl gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
          <group group_id="O2">
            <title>Epiduo Gel</title>
            <description>Epiduo gel was applied to one side of the face in a randomized fashion. This study product was applied once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Weeks 1 and 2</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" spread="0.69"/>
                    <measurement group_id="O2" value="2.23" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.76" spread="0.77"/>
                    <measurement group_id="O2" value="1.98" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8</title>
        <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
        <time_frame>Week 8</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clindoxyl Gel</title>
            <description>Subjects applied Clindoxyl gel to the entire face once-daily in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Product Acceptability and Preference Questionnaire - Overall Satisfaction of Study Product at Week 8</title>
          <description>Product Acceptability and Preference Questionnaire were completed by the subject at each timepoint using the following scale: 1, Very Satisfied; 2, Satisfied; 3, Neutral; 4, Unsatisfied; 5, Very Unsatisfied.</description>
          <population>ITT</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through Week 8.</time_frame>
      <desc>Any study product-related AEs ongoing at the end of the treatment period will be followed until they resolve, the condition stabilizes, the events are otherwise explained, or the subject is lost to follow-up. In addition, all SAEs will be followed until resolution as previously stated for study product-related AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Clindoxyl and Epiduo Gels</title>
          <description>Commencing at baseline, participants will apply clindoxyl and epiduo gels once daily in a bilateral split-face fashion (Split Face Treatment Period; allocation to left and right side randomly assigned) for an initial 2 weeks. At Week 5, during the Full Face Treatment Period, participants will apply clindoxyl gel to the entire face for an additional 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Application site irritation</sub_title>
                <counts group_id="E1" events="36" subjects_affected="36" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Application site dryness</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Application site exfoliation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If the Investigator wishes to make any such publication or presentation, the Investigator must first submit such publication or presentation to Stiefel for review at least thirty (30) days prior to the date on which such publication or presentation is proposed to be made.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>888-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

